News >

FDA Approves Ibrutinib Plus Obinutuzumab in Frontline CLL/SLL

Gina Columbus @ginacolumbusonc
Published: Monday, Jan 28, 2019

The FDA has approved the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) for the first-line treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x